Theravance Biopharma (TBPH) Operating Income (QoQ) (2013 - 2026)
Theravance Biopharma (TBPH) Operating Income (QoQ) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Theravance Biopharma | 864.82 Mn | 470.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -147.39% |
| Dec 31, 2025 | 410.02% |
| Sep 30, 2025 | -136.88% |
| Jun 30, 2025 | 81.12% |
| Mar 31, 2025 | -56.89% |
| Dec 31, 2024 | 15.11% |
| Sep 30, 2024 | 31.00% |
| Jun 30, 2024 | -40.14% |
| Mar 31, 2024 | -79.60% |
| Dec 31, 2023 | 28.77% |
| Sep 30, 2023 | 45.67% |
| Jun 30, 2023 | 35.28% |
| Mar 31, 2023 | -42.91% |
| Dec 31, 2022 | -90.64% |
| Sep 30, 2022 | 65.98% |
| Jun 30, 2022 | 30.19% |
| Mar 31, 2022 | 31.45% |
| Dec 31, 2021 | -4.76% |
| Sep 30, 2021 | 16.37% |
| Jun 30, 2021 | 23.58% |